Lantern Cost Of Revenue from 2010 to 2025

LTRN Stock  USD 3.90  0.08  2.09%   
Lantern Pharma Cost Of Revenue yearly trend continues to be very stable with very little volatility. Cost Of Revenue is likely to grow to about 211.1 K this year. During the period from 2010 to 2025, Lantern Pharma Cost Of Revenue quarterly data regression pattern had sample variance of 6.9 B and median of  1,627. View All Fundamentals
 
Cost Of Revenue  
First Reported
2010-12-31
Previous Quarter
201.1 K
Current Value
211.1 K
Quarterly Volatility
82.8 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lantern Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lantern Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 211.1 K, Interest Expense of 246.8 K or Selling General Administrative of 4.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.07. Lantern financial statements analysis is a perfect complement when working with Lantern Pharma Valuation or Volatility modules.
  
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

Latest Lantern Pharma's Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Lantern Pharma over the last few years. Cost of Revenue is found on Lantern Pharma income statement and represents the costs associated with goods and services Lantern Pharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Lantern Pharma's Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lantern Pharma's overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

Lantern Cost Of Revenue Regression Statistics

Arithmetic Mean53,675
Geometric Mean7,174
Coefficient Of Variation154.33
Mean Deviation71,345
Median1,627
Standard Deviation82,838
Sample Variance6.9B
Range209.5K
R-Value0.82
Mean Square Error2.4B
R-Squared0.67
Significance0.0001
Slope14,261
Total Sum of Squares102.9B

Lantern Cost Of Revenue History

2025211.1 K
2024201.1 K
2023174.8 K
2022154.7 K
202197.4 K
2020 3388.0

About Lantern Pharma Financial Statements

Lantern Pharma investors utilize fundamental indicators, such as Cost Of Revenue, to predict how Lantern Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue201.1 K211.1 K
When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:
Check out the analysis of Lantern Pharma Correlation against competitors.
To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.78)
Return On Assets
(0.34)
Return On Equity
(0.53)
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.